News and Updates

The EMA is adjusting its regulatory framework to align with the new EU Biotech Act, aiming to accelerate the approval of innovative biological therapies.

Eli Lilly reports positive early-stage clinical results for its latest JAK inhibitor, signaling a potential breakthrough in treating inflammatory diseases.

A new targeted drug strategy is showing potential to double survival rates for pancreatic cancer patients, marking a major breakthrough in oncology care.

New analysis reveals major reporting gaps in EU clinical trials, threatening medical transparency and patient safety. Read the implications for researchers.

New trial data suggests the tyrosine kinase inhibitor masitinib may improve five-year survival rates in ALS patients by targeting neuroinflammation.

The FDA has lifted a clinical hold on XBiotech's trial for axial spondyloarthritis. Learn how this move impacts the future of rheumatology drug development.

XBiotech has launched a Phase II trial for Vilamakitug, a novel IL-1α inhibitor aimed at treating patients with active axial spondyloarthritis.

A groundbreaking clinical trial has begun testing neural stem cell therapy as a potential treatment to repair brain damage in Huntington’s disease patients.

Novo Nordisk reports a major data breach affecting clinical trial files. Learn about the security risks and the impact on patient data protection.

Explore new Phase III results for tafasitamab in treating DLBCL. Learn how this combination therapy aims to improve progression-free survival in patients.